Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET

Background: Tumour necrosis factor‐alpha (TNF‐α) plays a crucial role in sarcoidosis. In severe disease, treatment with TNF‐α inhibitors may be effective. Objectives: Changes in sarcoid disease activity were assessed by fluorine‐18‐fluorodeoxyglucose positron emission tomography (FDG‐PET) in patie...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The clinical respiratory journal 2012-10, Vol.6 (4), p.238-247
Hauptverfasser:	Milman, Nils, Graudal, Niels, Loft, Annika, Mortensen, Jann, Larsen, Janni, Baslund, Bo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab Adult Aged Antibodies, Monoclonal, Humanized - therapeutic use Biopsy, Needle Cohort Studies Dose-Response Relationship, Drug Drug Administration Schedule Drug Therapy, Combination FDG-PET Female Fluorodeoxyglucose F18 Follow-Up Studies Humans Immunohistochemistry Injections, Subcutaneous Lung Diseases - diagnostic imaging Lung Diseases - drug therapy Lung Diseases - physiopathology Male Middle Aged Positron-Emission Tomography - methods Prednisolone - therapeutic use Prospective Studies Respiratory Function Tests sarcoidosis Sarcoidosis - diagnostic imaging Sarcoidosis - drug therapy Sarcoidosis - pathology Severity of Illness Index TNF-α TNF-α inhibitors Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor Necrosis Factor-alpha - therapeutic use
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!